CellCept (mycophenolate mofetil)

Manufacturer:
Genentech
Route of Administration: 
Oral
Site of Care:
Outpatient
Website: 
  • Manufacturer Website

Approved Indication:

prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogenic kidney, heart, or liver transplants, in combination with other immunosuppressants

Conditions:

  • Solid Organ Transplant

Therapeutic Area:

  • Gastroenterology
  • Rheumatology
  • Dermatology
  • Hepatology
  • Nephrology